CooperVision Proclear 1 Day: The FDA-Cleared Choice for Dry Eye Contact Lens Wearers

Contact lens-related dry eye is the leading cause of discontinuation among contact lens wearers—a clinical and commercial problem of significant magnitude for the eye care industry. Estimates suggest that between 30% and 50% of contact lens wearers experience symptomatic dry eye during lens wear, and a substantial proportion of these individuals discontinue lens wear entirely rather than accepting the discomfort or investigating alternative lens options.

This discontinuation rate represents not only a commercial loss for the industry but also a quality-of-life issue for patients who would prefer to remain in contact lenses but cannot tolerate the discomfort associated with their current lenses. CooperVision’s Proclear 1 Day addresses this population with a unique material technology that holds the distinction of being FDA-cleared with a specific dry eye comfort claim—a clinical validation that no other soft contact lens manufacturer has achieved. For dry eye sufferers who have been told that contact lenses are not for them, the Proclear 1 Day offers new hope and a clinically proven solution.

Phosphorylcholine: Nature’s Biocompatibility Solution

The Proclear lens family’s defining technology is phosphorylcholine (PC)—a naturally occurring molecule that forms the outer membrane of healthy human cells throughout the body. PC molecules have a distinctive chemical structure: one end is strongly hydrophilic (water-attracting), while the other end is lipophilic (fat-compatible). This amphiphilic character allows PC to integrate naturally with biological membranes while maintaining an aqueous surface layer that interfaces with the aqueous environment of the tear film, creating a surface that the biological systems of the eye recognize as familiar rather than foreign.

In the Proclear lens, PC molecules are chemically bonded to the omafilcon A hydrogel polymer network rather than simply blended with it. This covalent attachment ensures that PC molecules cannot leach from the lens material over time—they remain permanently integrated in the material matrix throughout the lens’s service life, providing consistent biocompatibility from the first wearing to the last.

The PC molecules present at the lens surface create a surface chemistry that the immune and biological systems of the eye recognize as “self” rather than “foreign,” minimizing the inflammatory and discomfort responses that can occur when the eye interacts with synthetic materials perceived as foreign bodies. This biocompatibility is the foundation of Proclear’s exceptional performance in dry eye patients, as it reduces the biological load on an already compromised ocular surface.

The FDA Dry Eye Comfort Claim

The FDA’s clearance of a specific labeling claim for Proclear lenses is remarkable in its specificity and clinical significance. The approved claim states that Proclear lenses “may provide improved comfort for people who experience mild discomfort or symptoms relating to dryness during lens wear.” This is not a general marketing claim but a specific clinical statement that the FDA permits on the basis of controlled clinical evidence demonstrating that Proclear wearers experience less dryness discomfort than wearers of other contact lens materials.

Obtaining this clearance required CooperVision to conduct controlled clinical trials comparing Proclear lenses to alternative materials in subjects with documented contact lens-related dry eye symptoms, demonstrating statistically significant improvement in comfort outcomes. The investment in clinical evidence generation reflects CooperVision’s confidence in the PC technology’s genuine performance differentiation—and the FDA’s granting of the claim reflects the clinical evidence’s validity. For practitioners and patients, the FDA clearance provides an evidence-based justification for selecting Proclear for dry eye patients, offering reassurance that the claimed benefits are supported by rigorous clinical testing rather than marketing hyperbole.

Omafilcon A Material Properties

The omafilcon A hydrogel material of the Proclear 1 Day maintains a water content of 60%—substantially higher than many silicone hydrogel daily disposables, which typically fall in the 30-55% range. This high water content contributes to the initial comfort sensation that many patients describe as immediately noticeable when switching from lower-water-content alternatives, and to the consistent wearing comfort that the PC technology helps sustain throughout the day. Unlike silicone hydrogel materials, omafilcon A does not require surface treatment or modification to achieve its wettability—the PC component provides inherent, permanent wettability throughout the material, eliminating the risk of surface coating degradation that can affect silicone hydrogel comfort over time.

The trade-off versus silicone hydrogel is oxygen transmissibility: omafilcon A’s Dk/t (oxygen transmissibility) is lower than silicone hydrogel alternatives, which may be a clinical consideration for patients who wear lenses for extended hours in conditions of reduced ambient oxygen. However, for the typical daily disposable wearer who removes lenses before sleep, the oxygen performance of omafilcon A is adequate for corneal health, and the comfort benefits of the PC technology outweigh the modest oxygen advantage of silicone hydrogel materials for most dry eye patients.

Suitability for New Contact Lens Wearers

The Proclear 1 Day’s combination of genuine biocompatibility, high water content, and the high initial comfort that PC technology consistently delivers makes it a particularly appropriate first lens choice for patients who are new to contact lens wear. New wearers have no established lens wear tolerance and are therefore more likely to notice and be discouraged by discomfort than experienced wearers who have adapted to the sensation of lens wear over time.

The Proclear 1 Day’s comfortable wearing experience from the first lens in the first wearing session supports the positive early experience that is critical for successful adaptation to contact lens wear and long-term patient retention in the contact lens modality. For practitioners fitting first-time wearers, selecting a lens that maximizes initial comfort increases the likelihood that the patient will successfully adapt to lens wear and continue with contact lenses as their primary vision correction modality. The Proclear 1 Day’s FDA clearance for dry eye comfort also provides a marketing advantage, as patients with even mild dry eye symptoms can be confidently fitted with a lens that has specific regulatory approval for their condition.

Clinical Management of Contact Lens-Related Dry Eye

For patients with moderate to severe dry eye, contact lens wear may require a broader clinical management approach that includes Proclear lenses as one component. Supplementary artificial tear use during wearing hours, use of omega-3 fatty acid supplements to support tear film lipid layer health, lid hygiene management, and environmental modifications (humidification, reduced screen time, avoidance of direct air currents) may all contribute to successful contact lens wear in dry eye patients who might otherwise be unable to tolerate lenses.

Proclear lenses should be considered as part of an integrated dry eye management strategy rather than as a standalone solution for severe dry eye. However, for patients with mild to moderate dry eye who have been unable to tolerate other contact lenses, the Proclear 1 Day often provides the breakthrough that allows successful lens wear. The lens’s biocompatibility reduces the inflammatory load on the ocular surface, while its high water content provides sustained hydration that counteracts the tear film instability characteristic of dry eye.

Conclusion: The Dry Eye Specialist’s Choice

The CooperVision Proclear 1 Day offers dry eye contact lens wearers something genuinely valuable: a clinically validated comfort advantage backed by the highest level of regulatory endorsement available in the contact lens category. The phosphorylcholine technology is not a marketing narrative but a genuine material science innovation with decades of clinical evidence supporting its biocompatibility and comfort performance. For patients who have struggled with contact lens-related dryness and discomfort, the Proclear 1 Day deserves evaluation as part of a comprehensive approach to comfortable contact lens wear, offering hope and proven performance where other lenses have failed.